Sage Therapeutic

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$8,654
$7,902
$77,972
$2,716
Gross Profit
7,247
6,633
77,152
1,811
EBITDA
-110,989
-116,742
-42,091
-144,321
EBIT
-111,300
-117,078
-42,500
-144,651
Net Income
-102,854
-108,483
-32,706
-201,630
Net Change In Cash
8,654
7,902
77,972
2,716
Free Cash Flow
-80,437
-37,832
-119,407
-136,194
Cash
101,233
173,985
70,992
148,712
Basic Shares
60,538
60,136
59,990
59,912

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$86,455
$7,686
$6,308
$1,114,200
Gross Profit
84,296
6,873
5,755
1,113,635
EBITDA
-511,684
-545,867
-456,727
651,712
EBIT
-513,077
-546,989
-460,909
649,082
Net Income
-541,489
-503,267
-450,827
606,073
Net Change In Cash
86,455
7,686
6,308
1,114,200
Cost of Revenue
-131,533
-1,367,296
1,533,726
Free Cash Flow
-541,138
-460,973
-378,554
663,935
Cash
70,992
162,700
294,233
1,661,082
Basic Shares
59,836
59,306
58,670
53,003

Earnings Calls

Quarter EPS
2024-06-30
-$1.70
2024-03-31
-$1.80
2023-12-31
-$1.80
2023-09-30
-$3.37